Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| EBPracticenet | UNKNOWN |
| Fonds National de la Recherche Scientifique | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this feasibility study is to evaluate the feasibility of an intervention, led by the pharmacist, aiming at benzodiazepines and z-drugs deprescribing in older adults living in the Belgian community setting. The main questions it aims to answer are:
Participants will receive an educational brochure from their pharmacist. Their pharmacist will also propose to send a new standardized form to their general practitioner to enhance collaboration about a potential benzodiazepine deprescribing.
Researchers will compare this intervention to usual care to see if the intervention is feasible and to gather first data on intervention effectiveness in benzodiazepine deprescribing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| END-IT intervention for the community setting | Experimental | The community pharmacist will distribute an educational brochure to the patient. He will also propose to the patient to communicate about a potential benzodiazepine deprescribing with his/her general practitioner through a document called pharmaceutical proposal. |
|
| Control | No Intervention | The participants will receive the usual care. The community pharmacists allocated to the control group will have access to the intervention material at the end of the study. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| END-IT intervention for the community setting | Other | The intervention was described in the arm/group descriptions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacists' adherence to the intervention | Has the intervention been implemented as intended? (e.g: global number of implemented intervention components) | At 3 months |
| Pharmacists' adherence to the intervention | Has the intervention been implemented as intended? (e.g: global number of implemented intervention components) | At 6 months |
| Participants' responsiveness | How far participants (pharmacists, patients, and general practitioners) have responded to the intervention and have been engaged by the intervention: e.g. number of altered prescriptions). | At 3 months |
| Participants' responsiveness | How far participants (pharmacists, patients, and general practitioners) have responded to the intervention and have been engaged by the intervention: e.g. number of altered prescriptions). | At 6 months |
| Feasibility of the recruitment process | The feasibility of the recruitment will be assessed (e.g. the ratio between the number of included patients and patients contacted for participation). | At 6 months |
| Feasibility of the data collection process | The feasibility of the data collection process will be assessed through the quality of the collected data (rate of missing data). | At 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Contextual factors potentially influencing the intervention effects at the patient-level. | Use of a questionnaire to assess factors that could explain potential differences in intervention implementation between patients. | At baseline |
| Contextual factors potentially influencing the intervention effects at the pharmacist-level. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Catherine Pétein, RN, MPH | Contact | +3227647236 | catherine.petein@uclouvain.be |
| Name | Affiliation | Role |
|---|---|---|
| Anne Spinewine, PhD | UCLouvain, Louvain Drug Research Institute/Clinical pharmacy research group | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLouvain | Recruiting | Woluwe-Saint-Lambert | 1200 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40037665 | Derived | Petein C, Chevallereau T, Aikpitanyi J, Evrard P, Tubeuf S, Henrard S, Spinewine A. Protocol to evaluate the feasibility of the D-PRESCRIBE intervention adapted to the Belgian community setting (END-IT CS study). BMJ Open. 2025 Mar 4;15(3):e085434. doi: 10.1136/bmjopen-2024-085434. |
Not provided
Not provided
Only publishable project data relating to the main analysis and research output will be shared on a data repository after an embargo period of 2 years after June 2024. All relevant documentation necessary to facilitate data re-use will be shared along with the datasets.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Use of a questionnaire to assess factors that could explain potential differences in intervention implementation between pharmacies. |
| At baseline |
| Mechanisms of impact potentially influencing the intervention | Use a questionnaire to assess mechanisms of impact in relation with how the intervention is supposed to have its effects. | At baseline |
| Mechanisms of impact potentially influencing the intervention | Use of a questionnaire to assess mechanisms of impact in relation with how the intervention is supposed to have its effects. | At 3 months |
| Mechanisms of impact potentially influencing the intervention | Use of a questionnaire to assess mechanisms of impact in relation with how the intervention is supposed to have its effects. | At 6 months |
| Exploratory benzodiazepine deprescribing rate analysis | Defined as benzodiazepine reduction or cessation at 6 months | At 3 months |
| Exploratory benzodiazepine deprescribing rate analysis | Defined as benzodiazepine reduction or cessation at 6 months | At 6 months |